GlaxoSmithKline (GSK) has provided results from its first clinical trial assessing use of its pandemic (H1N1) adjuvanted vaccine. The results demonstrate that after one dose the candidate vaccine
Rib-X Pharmaceuticals (Rib-X) plans to enter into a Clinical Trials Agreement with the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of
Celldex Therapeutics (Celldex) has reported the first patient dosing in a phase 1/2 study of its vaccine candidate, CDX-1401, in patients with malignant solid tumors that express NY-ESO-1.
Regeneron has completed patient enrollment in two randomised, double-masked, phase 3 clinical trials evaluating VEGF Trap-Eye in the treatment of the neovascular form of age-related macular degeneration (wet
Artielle ImmunoTherapeutics (Artielle) has provided the results of a phase 1 safety study of RTL1000, a recombinant T-Cell receptor ligand specific for an immunodominant MOG peptide, in multiple
AVI BioPharma has announced presentation of data regarding the company’s antisense technology for control of the immune response in hemorrhagic virus infections, including Ebola and Marburg virus, at
ARIAD reports result of first interim analysis of phase 3 SUCCEED trial of oral ridaforolimus, an investigational mTOR inhibitor, in metastatic sarcomas. The company said that the phase
Aeolus Pharmaceuticals has initiated second study in mice, to determine the optimal length of treatment with AEOL 10150 when used as a countermeasure to Acute Radiation Syndrome (ARS)
Merck has provided new data from a phase IIB clinical study of odanacatib, oral, once-weekly investigational treatment for osteoporosis. The data showed that when stopping treatment after two
Study demonstrating, Cardium’s Gene Activated Matrix or GAM technology accelerates periodontal tissue regeneration of oral implant-supporting wounds, was published in the scientific journal, Gene Therapy. According to Cardium,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.